Timothy Mullett, MD, leaned toward his computer screen as he spoke, drowning out the sounds of the busy coffee shop behind him to get his message across.
Three tobacco giants are proposing to pay close to $25 billion to provinces and territories and more than $4 billion to tens ...
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...
The Canadian Press on MSN1h
Tobacco settlement will not protect future generations from addiction: advocatesThe Canadian Cancer Society and other health advocates say a proposed settlement that may see tobacco companies pay out ...
Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
The FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 ...
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...
The narrative spans four generations, highlighting the hereditary nature of breast cancer and its impact on family dynamics.
The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...
Carle Health and OSF HealthCare are working to bring lifesaving screening to the uninsured and the underinsured. As part of ...
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval.
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback